<DOC>
	<DOC>NCT00738296</DOC>
	<brief_summary>Comparison of the effect on the progression of the carotid intima-media interphase thickness (GIM), arterial rigidity according to the measurement of the pulse wave speed and direct measurement of the carotid and aortic rigidities and an inflammation marker (PCR) in patients with established cardiovascular disease (myocardial infarct, atherosclerotic coronary disease), diabetes mellitus type 2 or equivalent risk of coronary disease and a low density lipoprotein level &gt; 100 mg/dL, treated with simvastatin, pravastatin or the combination of simvastatin-ezetimibe during a period of at least one year.</brief_summary>
	<brief_title>Vytorin on Carotid Intima-media Thickness and Overall Rigidity</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
	<criteria>LdlC Levels &gt;100 Mg/Dl Patients Who Have Signed The Consent Patients Of ages between 30 and 75 Years Old Patients Of Both Genders Patients With Established Cardiovascular Disease, Diabetes With Or Without Established Cardiovascular Disease Patients Without Previous Treatment With Ezetimibe</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2008</verification_date>
</DOC>